UniProtKB/Swiss-Prot P02679: Variant p.Asp356Tyr

Fibrinogen gamma chain
Gene: FGG
Feedback?

Variant information Variant position:

356 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Aspartate (D) to Tyrosine (Y) at position 356 (D356Y, p.Asp356Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and acidic (D) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In Kyoto-3; impaired polymerization. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs121913093 [ dbSNP | Ensembl ]

Sequence information Variant position:

356 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

453 The length of the canonical sequence.
Location on the sequence:

MQFSTWDNDNDKFEGNCAEQ D GSGWWMNKCHAGHLNGVYYQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQ

Mouse                         MQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYHQ

Rat                           MHFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQ

Bovine                        MQFSTWDSDNDKYDGNCAEQVGIGWWMNKCHAGHLNGVYYQ

Xenopus laevis                MQFSTFDKDNDKFDGNCAEQDGSGWWMNRCHAAHLNGKYYQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	27 – 453	Fibrinogen gamma chain
Domain	170 – 416	Fibrinogen C-terminal
Binding site	344 – 344
Binding site	346 – 346
Binding site	348 – 348
Binding site	350 – 350
Disulfide bond	352 – 365
Helix	352 – 356

Literature citations
Gene analyses of abnormal fibrinogens with a mutation in the gamma chain.
Mimuro J.; Muramatsu S.; Maekawa H.; Sakata Y.; Kaneko M.; Yoshitake S.; Okuma M.; Ito Y.; Takeda Y.; Matsuda M.;
Int. J. Hematol. 56:129-134(1992)
Cited for: VARIANTS CYS-301; LYS-334; THR-336 AND TYR-356; Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization.
Terukina S.; Yamazumi K.; Okamoto K.; Yamashita H.; Ito Y.; Matsuda M.;
Blood 74:2681-2687(1989)
Cited for: VARIANT KYOTO-3 TYR-356;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.